Company intelligence / Profile preview
Fubei Biotechnology
Suzhou, Jiangsu, Chinafubio.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Fubei Biotechnology is a Chinese biotech platform company focused on developing novel neurological drugs using monoclonal antibodies and gene delivery technologies. Its lead asset FB-1001 targets TrkB for ischemic optic neuropathy and is in Phase 1 trials. The broader pipeline includes programs at discovery through preclinical stages targeting nervous system disorders with antibody-based modalities. No published clinical results were found.
- Therapeutic areas
- Ophthalmology
- Modalities
- Monoclonal antibodyAntibodyGene therapyViral vector-based therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Fubei Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fubei Biotechnology.